# A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

> **NCT05241613** · PHASE1 · TERMINATED · sponsor: **Accutar Biotechnology Inc** · enrollment: 28 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** AC176

## Key facts

- **NCT ID:** NCT05241613
- **Lead sponsor:** Accutar Biotechnology Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-16
- **Primary completion:** 2024-03-05
- **Final completion:** 2024-03-05
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05241613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05241613, "A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05241613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*